|
Daily Medical Update
Bacterial peritonitis
Saturday, September 05, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Gastroenterologia y hepatologia (2025) - Meta-Analysis
Key Findings
- mNGS detected pathogens in SBP ascites with pooled sensitivity of 94% (95% CI 86%-97%) and specificity of 81% (95% CI 71%-89%).
- Diagnostic discrimination was high, with an area under the curve of 0.95 (95% CI 0.92-0.96).
- Gram-positive bacteria were the most frequently identified pathogen group (36%), followed by Gram-negative bacteria (29%), viruses (22%), and fungi (11%).
📋 Practice Implication: mNGS may be useful when rapid, broad pathogen identification could refine SBP antimicrobial selection, but its imperfect specificity warrants correlation with clinical findings and conventional testing.
|
International journal of antimicrobial agents (2026) - Systematic Review
Key Findings
- SBP represented 89% of the reported non-bloodstream infections in adults with cirrhosis, and Gram-negative organisms accounted for 60% of isolates.
- The pooled multidrug-resistance proportion was 23% (95% CI 13%-37%), with higher burdens in lower-middle-income countries (56%) than in the other income groups (15%-41%).
- Resistance markers varied geographically; lower-middle-income settings had ESBL prevalence of 24%, VRE 23%, and CRE 32%, compared with 8%-10%, 2%, and 1%, respectively, in comparator settings.
📋 Practice Implication: Empiric SBP treatment should incorporate local resistance data and recent healthcare or geographic exposures, with early de-escalation guided by cultures and susceptibility results.
|
The Cochrane database of systematic reviews (2026) - Systematic Review
Key Findings
- Compared with no intervention, albumin showed little to no difference in all-cause mortality (RR 0.80, 95% CI 0.53-1.20; 8 studies, 845 participants), with very uncertain evidence.
- Albumin may reduce kidney impairment versus no intervention (RR 0.51, 95% CI 0.28-0.93; 7 studies, 768 participants), but the evidence was very uncertain.
- Compared with other intravenous fluids, albumin showed little to no difference in kidney impairment (RR 0.77, 95% CI 0.53-1.10) and mortality (RR 1.05, 95% CI 0.85-1.29), both with very low-certainty evidence.
📋 Practice Implication: Albumin should not be assumed to improve survival in cirrhosis with bacterial infection; use should be individualized while awaiting more certain evidence, particularly when renal-protection benefits are being considered.
|
Hepatology international (2025) - Randomized Controlled Trial
Key Findings
- In hemodynamically stable Child-Pugh A cirrhosis after upper-GI bleeding, day-5 infection rates were 7.0% without prophylaxis versus 11.6% with ceftriaxone; withholding antibiotics was non-inferior at the prespecified margin.
- SBP after post-bleed ascites was the most common infection site, accounting for 10 of 16 infections (66.7%) across both groups.
- Failure to control bleeding and mortality were comparable: day-5 mortality was 0% versus 2.5%, and 6-week mortality was 1.4% versus 2.5%, without prophylaxis versus ceftriaxone, respectively.
📋 Practice Implication: For carefully selected, stable Child-Pugh A patients with upper-GI bleeding, withholding routine prophylactic antibiotics can reduce exposure without an observed increase in short-term infection or mortality.
|
Journal of hepatology (2025) - Randomized Controlled Trial
Key Findings
- Rifaximin did not improve 12-month survival versus placebo (56.6% vs 68.1%; p = 0.74) in severe cirrhosis with low-protein ascites.
- Rifaximin did not improve 3-month survival (82.6% vs 75.4%) or 6-month survival (76.4% vs 71.1%) and did not reduce the incidence of cirrhosis complications, including SBP, hepatic encephalopathy, gastrointestinal bleeding, or hepatorenal syndrome.
- Rifaximin was well tolerated throughout the trial; a reduction in 12-month cumulative incidence of liver-related events was observed only in the adherent per-protocol subgroup.
📋 Practice Implication: Routine rifaximin primary prophylaxis should not be expected to improve survival or prevent cirrhosis complications in this population; adherence-related subgroup signals remain hypothesis-generating.
|
|
💡
Summary
Recent evidence emphasizes pathogen-directed diagnosis and locally informed empiric therapy for spontaneous bacterial peritonitis (SBP), with mNGS showing high sensitivity but imperfect specificity and antimicrobial resistance remaining substantial in cirrhosis-associated infections. Adjunctive albumin has uncertain effects on mortality and kidney impairment, while trials found no survival or complication benefit from rifaximin primary prophylaxis and no excess infection risk when prophylactic antibiotics were withheld after upper-GI bleeding in hemodynamically stable Child-Pugh A patients.
|
|